5 million to IDEC
as an option fee and will reimburse up to $1.
As a result of this expanded agreement, IDEC
and Genentech now
Pharmaceuticals is focused on the development of targeted immunotherapies for the treatment of cancers and autoimmune diseases.
president and chief executive officer.
The PRIMATIZED anti-CD4 antibody central to the joint development program with SmithKline Beecham is one of a new class of genetically engineered antibodies developed by IDEC
Grillo-Lopez, MD, IDEC
Pharmaceuticals' vice president of medical and regulatory affairs.
Our new Phase II trial using IDEC
-C2B8 in combination with chemotherapy is an additional step in its development to show the breadth of applications for antibody therapy of lymphoma," said William Rohn, senior vice president commercial and corporate development of IDEC
We are very pleased to be collaborating with IDEC
Pharmaceuticals and are excited about the potential development of a PRIMATIZED antibody for use in the long-term treatment of serious immune-mediated diseases that currently do not have adequate therapy.
also announced today that based on independent, encouraging Phase I/II clinical trial testing with both MELIMMUNE-1 and MELIMMUNE-2, the company plans to develop the two product candidates as a single, bivalent vaccine.
Rastetter, President and CEO of IDEC
vice president of medical and regulatory affairs of IDEC
To phase out the SPECIFID program, IDEC
will record a $3.